Results 51 to 60 of about 7,007,196 (291)

In Silico to In Cerebro—Development of the Orexin Receptor Antagonist “Photorexant” for Photomodulation In Vitro and in Mouse Brains

Angewandte Chemie International Edition, EarlyView.
Following a structure‐based design approach, photoswitchable derivatives of the FDA‐approved drug suvorexant were designed, docked, synthesized, and characterized pharmacologically at the orexin 1 and 2 receptors (OX1R and OX2R). Optimized “photorexant” showed up to an 11‐fold difference in IC50 between photoisomers, enabled dynamic and reversible ...
Marcus Angermann, Marie H. Deventer, Vicente Ledesma‐Martin, Nuno Martinho, Alix Flake, Silvia Mori, Angel Nuñez, Jaime Pignatelli, Rita C. Guedes, Christophe P. Stove, Michael Decker   +10 more
wiley   +1 more source

Kappa Opioid Regulation of Stress-Related Behavior [PDF]

, 2010
Anxiety disorders affect roughly 40 million American adults in a given year. Those suffering from anxiety disorders often experience additional stress-linked illnesses, such as depression.
Harshberger, Erin
core  

Development of a nalmefene formulation suitable for a community‐use auto‐injector

British Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano, Manjunath S. Shet, Hugh Huang, Ronnie Ortiz, Garth T. Whiteside, Glen Apseloff, Stephen C. Harris   +6 more
wiley   +1 more source

Adverse effects of opioids prescribed in opioid agonist treatment: a systematic review protocol

, 2023
Background: Opioid agonist treatment (OAT) comprises the use of opioid agonists to replace illicit street opioids and is the treatment of choice for individuals with opioid use disorder (OUD). We aim to systematically review the risk for any type of adverse effects of OAT in patients with opioid use disorder.Methods: We aim to inform evidence-based ...
Maximilian Meyer, Christian Appenzeller-Herzog, Marco Cattaneo, Lars G. Hemkens   +3 more
openaire   +1 more source

Rescue Analgesia for Opioid-Dependent Individuals on Opioid Agonist Treatment during Hospitalization: Adherence to Guideline Treatment

European Addiction Research, 2023
Introduction: Opioid agonist treatment (OAT) is the first-line treatment for opioid use disorder (OUD). Simultaneously, opioids are essential medicines in acute pain management. The literature is scarce on acute pain management in individuals with OUD, and guidelines are controversial for patients on OAT.
Isabelle Arnet, Kenneth M. Dürsteler, Christine Jaiteh, Florian Grossmann, Kurt E. Hersberger   +4 more
openaire   +2 more sources

Paediatric clonidine medication errors: Findings from a multicentre French study

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to describe the characteristics of medication errors involving clonidine in paediatric patients and reported to French Network of Pharmacovigilance and Poison Control Centres. Methods This retrospective observational study analysed clonidine‐related medication errors reported between 1985 and June 2024 in patients under 12 years ...
Eve‐Marie Thillard, Anthony Facile, Marion Lepelley, Morgane Cellier, Laurent Chouchana, Sophie Gautier, Ramy Azzouz, Thierry Vial, Annie‐Pierre Jonville‐Bera   +8 more
wiley   +1 more source

The journey of opioid substitution therapy in India: Achievements and challenges

Indian Journal of Psychiatry, 2017
Opioids are one of the most problematic illegal substances globally. Opioid abuse is associated with complications in various spheres of the user's life, his/her family, and the society.
Ravindra Rao
doaj   +1 more source

Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley   +1 more source

National opioid pharmacotherapy statistics annual data collection 2012 [PDF]

, 2013
On a snapshot day in 2012, almost 47,000 clients received pharmacotherapy treatment for their opioid dependence at 2,226 dosing points around Australia, this report finds.SummaryAlmost 47,000 Australians received pharmacotherapy treatment for their ...

core  

Acute toxic leucoencephalopathy following protonitazene ingestion

British Journal of Clinical Pharmacology, EarlyView.
Background Distribution of illicit counterfeit alprazolam containing the highly potent synthetic opioid‐receptor agonist protonitazene recently resulted in a number of severe overdoses in Ireland. We report three cases that presented to our hospital, within 6 weeks of one another, following ingestion of illicitly‐sourced alprazolam.
Ruadhan O'Laoi, Holly Acton, Pierce Kavanagh, Isabelle Hunt, Niall Sheehy, Cormac Kennedy   +5 more
wiley   +1 more source